Krystal Biotech (KRYS) Net Margin: 2021-2025
Historic Net Margin for Krystal Biotech (KRYS) over the last 2 years, with Sep 2025 value amounting to 81.15%.
- Krystal Biotech's Net Margin rose 4875.00% to 81.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 53.30%, marking a year-over-year increase of 3163.00%. This contributed to the annual value of 30.69% for FY2024, which is 913.00% up from last year.
- According to the latest figures from Q3 2025, Krystal Biotech's Net Margin is 81.15%, which was up 103.32% from 39.91% recorded in Q2 2025.
- Krystal Biotech's Net Margin's 5-year high stood at 1,059.79% during Q1 2021, with a 5-year trough of 2.06% in Q1 2024.
- For the 3-year period, Krystal Biotech's Net Margin averaged around 136.94%, with its median value being 39.91% (2025).
- Per our database at Business Quant, Krystal Biotech's Net Margin plummeted by 91,134bps in 2024 and then surged by 4,875bps in 2025.
- Quarterly analysis of 4 years shows Krystal Biotech's Net Margin stood at 1,059.79% in 2021, then reached 20.62% in 2023, then soared by 2,933bps to 49.95% in 2024, then spiked by 4,875bps to 81.15% in 2025.
- Its Net Margin was 81.15% in Q3 2025, compared to 39.91% in Q2 2025 and 40.47% in Q1 2025.